MS: is it one disease?
暂无分享,去创建一个
J. Pollard | M. Barnett | J. Parratt | M H Barnett | J W Prineas | J. Prineas | J D E Parratt | J D Pollard | Michael H Barnett | John D. Pollard
[1] David H. Miller,et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.
[2] C. Lucchinetti,et al. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. , 2001, Trends in molecular medicine.
[3] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[4] Jacqueline Palace,et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS , 1999, Neurology.
[5] Ichiro Nakashima,et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.
[6] J. Prineas,et al. Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown , 1981, Annals of neurology.
[7] R. Ravid,et al. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity , 2004, Annals of neurology.
[8] C. Polman,et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology , 2005, Journal of Neuroimmunology.
[9] J. Zajicek,et al. Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. , 1992, Brain : a journal of neurology.
[10] David H. Miller,et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis , 2004, Journal of Neurology.
[11] R. Hohlfeld,et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. , 2002, Brain : a journal of neurology.
[12] B. Weinshenker,et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange , 2005, The Lancet.
[13] Sergio E. Baranzini,et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets , 2008, Nature.
[14] M. Barnett,et al. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.
[15] D. Arnold,et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.
[16] A. Bar-Or,et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions , 2003, Journal of Neuroimmunology.
[17] L. Bö,et al. Homogeneity of active demyelinating lesions in established multiple sclerosis , 2008, Annals of neurology.
[18] H. Lassmann,et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation , 2002, Nature Medicine.
[19] M. Barnett,et al. The pathology of multiple sclerosis: a paradigm shift , 2006, Current opinion in neurology.
[20] H. Link,et al. Review: cytokines and the pathogenesis of multiple sclerosis , 1996, Journal of neuroscience research.
[21] M. Barnett,et al. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion , 2006, Multiple sclerosis.
[22] J. Merrill. Proinflammatory and Antiinflammatory Cytokines in Multiple Sclerosis and Central Nervous System Acquired Immunodeficiency Syndrome , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[23] J. Parisi,et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.
[24] L. Boon,et al. Transfer of Central Nervous System Autoantigens and Presentation in Secondary Lymphoid Organs1 , 2002, The Journal of Immunology.
[25] C. Raine,et al. The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.
[26] Hans Lassmann,et al. Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction , 2000, The Journal of experimental medicine.
[27] A. Verkman,et al. The Journal of Experimental Medicine CORRESPONDENCE , 2005 .
[28] J. Benjamins,et al. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[29] Helmut Butzkueven,et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival , 2002, Nature Medicine.
[30] H. Lassmann,et al. Autoimmunity to Myelin Oligodendrocyte Glycoprotein in Rats Mimics the Spectrum of Multiple Sclerosis Pathology , 1998, Brain pathology.
[31] Moses Rodriguez,et al. Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.
[32] V. Kostulas,et al. Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. , 1987, Archives of neurology.
[33] C. Raine,et al. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions , 1976, Neurology.
[34] G. Reichmann,et al. Brain Dendritic Cells and Macrophages/Microglia in Central Nervous System Inflammation1 , 2001, The Journal of Immunology.
[35] H. Lipton,et al. A specific viral cause of multiple sclerosis: One virus, one disease , 2007, Annals of neurology.
[36] A. Coles,et al. Campath-1H Treatment of Multiple Sclerosis , 2007, Neurodegenerative Diseases.
[37] D. Hoyer,et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. , 2008, Pharmacology & therapeutics.
[38] H. Lassmann,et al. Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination , 1998, Annals of neurology.
[39] S. Ludwin,et al. Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. , 2005, Brain : a journal of neurology.
[40] T. Olsson,et al. Immunoblot detection of oligoclonal anti‐myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis , 1987, Neurology.
[41] C. Granger,et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1 , 1999, Journal of Neuroimmunology.
[42] Hans Lassmann,et al. Hypoxia-like tissue injury as a component of multiple sclerosis lesions , 2002, Journal of the Neurological Sciences.
[43] M. Esiri,et al. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. , 1997, Brain : a journal of neurology.